RZLT Rezolute Inc
Company Analysis
Latest News
Rezolute's FDA Pre-BLA Nod Sends Shares Soaring, But Can a Failed Trial Really Lead to an Approval?
Shares of Rezolute surged 11% to $4.45 after the FDA took the unusual step of recommending a pre-BLA meeting — essentially an invitation to discuss filing for...
🟢 Rezolute is trading 11% up today after FDA recommended pre-BLA meeting for ersodetug
Rezolute is trading 10.99% up at $4.45 after the FDA recommended a pre-BLA meeting for ersodetug. - The October 5, 2026, gain followed the recommendation,...
🟢 Rezolute is trading 5% up today after FDA recommended a pre-BLA meeting for ersodetug
Rezolute is trading at $4.22, up 5.24%, with the FDA’s pre-BLA meeting recommendation for ersodetug the clearest explanation for the gain. - On October 5,...
FDA Recommends Pre-BLA Meeting for Rezolute's Congenital HI Drug Ersodetug
Rezolute, Inc. announced that the U.S. Food and Drug Administration (FDA) has recommended the company request a pre-BLA (Biologics License Application) meeting...
🟢 Rezolute is trading 13.72% up in pre-market with no clear catalyst identified
Rezolute is trading at $4.56, up +13.72% in pre-market, with no clear catalyst established. - No fresh company announcement explaining the October 5...
🟢 Rezolute is trading 8.7% up in pre-market
Rezolute is trading at $4.50, up 8.70% in pre-market, with no confirmed catalyst identified. - Craig-Hallum upgraded Rezolute to Buy on September 29 and...
🟢 Rezolute is trading 5.8% up today without a fresh company announcement
Rezolute is trading 5.8% up at $4.33 on September 30, 2026; no fresh company announcement surfaced to explain the move. - On September 29, Craig-Hallum...
🟢 Rezolute is trading 7% up today amid Craig-Hallum's reported Buy upgrade
Rezolute is trading at $4.47, up 7.06%, with a same-day analyst upgrade a plausible catalyst. - The supplied live price context is timestamped 9:34 a.m. EST on...
Craig-Hallum's Buy Call on Rezolute Implies 56% Upside — But Can a Single Drug Trial Justify That Bet?
Shares of Rezolute Inc. surged 7.7% in pre-market trading to $4.50 on September 29 after Craig-Hallum reportedly upgraded the stock to Buy and slapped a $7...
🟢 Rezolute is trading 8% up in pre-market after a Craig-Hallum upgrade to Buy
Rezolute is trading at $4.50, up 7.66%, in pre-market on September 29, with a Craig-Hallum Buy upgrade as the clearest fresh potential catalyst. -...
🟢 Rezolute is trading 5% up with no clear catalyst identified
Rezolute is trading 5.26% higher at $4.11, but no confirmed catalyst has been identified for the advance. - No company-specific announcement dated September...
Rezolute reports fourth quarter 2026 net loss of $20.5 million and clinical progress in tumor HI
Rezolute reported a narrowed net loss of $20.5 million for the fourth quarter ended June 30, 2026, as the company focused on late-stage clinical development...
🔴 Rezolute is trading 5.6% down today
Rezolute is trading 5.6% down at $3.73, with no clear company-specific catalyst identified for September 18, 2026. - FDA review of additional ersodetug data...
Rezolute reports Q4 results, highlighting FDA review of ersodetug
Rezolute, Inc. will release its fourth-quarter 2026 earnings after market close on Wednesday, Sept. 16, 2026. Analysts forecast a loss of $0.1479 per share for...
🔴 Rezolute is trading 5.3% down today as broader biotech weakness intensified
Rezolute is trading 5.3% down at $3.93 after broader biotech weakness intensified on September 16, 2026. - The XBI biotech ETF is down 2.11% during regular...
Rezolute Inc Q2 2026 Earnings Preview: What Analysts Expect on September 16, 2026
Rezolute Inc is expected to report a consensus EPS loss of $0.14 on zero revenue for the quarter ending June 30, 2026, with its current stock price of $4.22...
🟢 Rezolute is trading 6% up today after the FDA continued reviewing failed Phase 3 data
Rezolute is trading at $4.29, up +5.67%, rebounding after announcing on September 9, 2026 that the FDA continues reviewing data from its failed Phase 3 sunRIZE...
Rezolute's Failed Trial Still Has the FDA Talking — Is That Enough to Justify a $440 Million Bet?
Shares shifted as Rezolute (RZLT) jumped +10.84% to $4.50 on September 10, defying a down market after disclosing that the FDA's review of its failed Phase 3...
🟢 Rezolute is trading 11% up today in pre-market as FDA continues reviewing Phase 3 sunRIZE data
Rezolute is trading 10.84% up now at $4.50 in pre-market after its September 9, 2026 update said the FDA’s review of additional Phase 3 sunRIZE data remains...
🟢 Rezolute is trading 5.77% up today in pre-market as FDA continues reviewing Phase 3 sunRIZE data
Rezolute is trading at $4.29, up 5.77% in pre-market after its September 9, 2026 update that the FDA continues reviewing Phase 3 sunRIZE data. - The study...